EN DE

Lucy Scientific Discovery Inc (LSDIF) Fair Value & Analysis

Healthcare · US · Market cap $176

LS Lucy Scientific Discovery Inc logo Lucy Scientific Discovery Inc LSDIF · US
Price$0.0001
Fair Value$0.0001
Upside+0.0%
Quality19/100
Watch Lucy Scientific Discovery Inc for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.0% net margin
negative free cash flow
Trails peers (2/7)
Narrow moat 23/100
Evidence: Low Range $0.0001 – $0.0001 Share as image

Fair value as of: Aug 19, 2026

From 1 valuation models · updated today

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (4 years)

$32.90 $0.0001 Fair Value $0.0001 Feb 2023 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

42‑month range $0.0001 – $32.90 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Lucy Scientific Discovery Inc (LSDIF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at $16.7K. Fundamentals as of Aug 19, 2026

For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, LSDIF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0001 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 50

Notify me when LSDIF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $16.7K
Free cash flow −$4.6M FY2023
Operating margin -8,907%
EPS (TTM) $-76.41

Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 19/100

Of which business quality 23 · Market factors (momentum, volatility) 41

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products.

Full company description

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2023 · reported fiscal years

Lucy Scientific Discovery Inc reported revenue of $7.0K in FY2023 versus $0 in FY2021. Reported net income was −$9.0M in FY2023.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Revenue
FY21 $0
FY22 $0
FY23 $7.0K
Net income
FY21 −$4.7M
FY22 −$5.9M
FY23 −$9.0M

Watch LSDIF: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Lucy Scientific Discovery Inc Fair Value". https://www.fairvalue-calculator.com/stock/LSDIF

Peer Group

Drug Manufacturers - Specialty & Generic · 632 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 23 · Bottom 25%
Fair Value upside +0% · Above median
Return on assets -99% · Bottom 25%
Net margin (TTM) 0% · Below median
Revenue growth 0% · Below median

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.01× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 33 · sector 7
FUTURE 0 · sector 20
PAST 0 · sector 24
HEALTH 0 · sector 97
DIVIDEND 0 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Lucy Scientific Discovery Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Lucy Scientific Discovery Inc (LSDIF) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% (fairly valued).
What is the fair value of LSDIF?
Our model-based fair value for Lucy Scientific Discovery Inc is $0.0001 (as of Aug 19, 2026), built from audited fundamentals. The current price is $0.0001.
What is the quality score of LSDIF?
Lucy Scientific Discovery Inc has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Lucy Scientific Discovery Inc (LSDIF)?
Lucy Scientific Discovery Inc reported trailing-twelve-month revenue of about $16.7K (latest available figure, as of Aug 19, 2026).
What is the net profit margin of LSDIF?
The net profit margin of Lucy Scientific Discovery Inc is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Lucy Scientific Discovery Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.